Ipsen has agreed to sell its rare pediatric disease priority review voucher to a large global pharmaceutical company for $158 million.

Congratulations to our Rainmakers Rohit Sachdev and Tony Chan and Rising Star Joseph Santiesteban.

The investment marks the first time MY DR NOW has received external capital.

Advised NextCapital, an open-architecture digital retirement advice provider based in Chicago, on its acquisition by Goldman Sachs.

The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor.

Orrick is advising Smash Capital on its investment in Singapore-based digital content monetization platform Coda Payments.